John Hussman's RPRX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 21,000 shares of Royalty Pharma plc (RPRX) worth $1.18 M, representing 0.27% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, John Hussman has maintained this position in RPRX for several quarters, showing initial confidence in the investment. Largest reduction occurred in Q1 2026, reducing 42,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Royalty Pharma plc (RPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Royalty Pharma plc (RPRX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -42,000 | Reduce 66.67% | 21,000 | $47.97 |
| Q4 2025 | +63,000 | New Buy | 63,000 | $38.64 |
John Hussman's Royalty Pharma plc Investment FAQs
John Hussman first purchased Royalty Pharma plc (RPRX) in Q4 2025, acquiring 63,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Royalty Pharma plc (RPRX) for 3 quarters since Q4 2025.
John Hussman's largest addition to Royalty Pharma plc (RPRX) was in Q4 2025, adding 63,000 shares worth $2.43 M.
According to the latest 13F filing for Q2 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 21,000 shares of Royalty Pharma plc (RPRX), valued at approximately $1.18 M.
As of the Q2 2026 filing, Royalty Pharma plc (RPRX) represents approximately 0.27% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Royalty Pharma plc (RPRX) was 63,000 shares, as reported at the end of Q4 2025.